{"doi":"10.1002/hon.3134","title":"Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:p>\n                    Fluorescence in situ hybridization (FISH) to detect the recurrent cytogenetics abnormalities deletion 13q, trisomy 12, deletion 11q, and deletion 17p is important for prognostication in chronic lymphocytic leukemia (CLL). A subset of patients are negative for each of these abnormalities (normal 12/13/11/17 FISH), and outcomes are heterogenous within this group. To elucidate variables important for prognostication in this subgroup we conducted a retrospective analysis of 280 treatment‐naïve CLL patients with normal standard CLL FISH results. In a multivariable model, advanced Rai stage (\n                    <jats:italic>p</jats:italic>\n                     = 0.04, hazard ratio [HR] 1.24 (95% confidence interval [CI] 1.01–1.53)), unmutated immunoglobulin heavy chain gene (\n                    <jats:italic>IGHV</jats:italic>\n                    ) (\n                    <jats:italic>p</jats:italic>\n                     &lt; 0.0001, HR 5.59 (95% CI 3.63–8.62)) and\n                    <jats:italic>IGH</jats:italic>\n                    rearrangement by FISH (\n                    <jats:italic>p</jats:italic>\n                     = 0.02, HR 2.56 (95% CI 1.20–5.48)) were significantly associated with shorter time to first treatment. In a multivariable model for overall survival, increasing age at 5‐year increments (\n                    <jats:italic>p</jats:italic>\n                     &lt; 0.0001, HR 1.55 (95% CI 1.25–1.93)), unmutated\n                    <jats:italic>IGHV</jats:italic>\n                    (\n                    <jats:italic>p</jats:italic>\n                     = 0.01, HR 5.28 (95% CI 1.52–18.35)) and gain of\n                    <jats:italic>REL</jats:italic>\n                    (\n                    <jats:italic>p</jats:italic>\n                     = 0.01, HR 4.08 (5% CI 1.45–11.49)) were significantly associated with shorter survival. Our study identifies variables important for refining prognosis for CLL patients with normal standard CLL FISH results.\n                  </jats:p>","journal":"Hematological Oncology","year":2023,"id":637898,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":405030,"name":"Ying Huang","orcid":"0000-0001-5265-3984","position":1,"is_corresponding":false},{"id":1656533,"name":"Jonathan Hyak","orcid":"0000-0001-7039-0655","position":2,"is_corresponding":false},{"id":511547,"name":"John C. Byrd","orcid":"0000-0002-8778-1000","position":3,"is_corresponding":false},{"id":278932,"name":"Seema A. Bhat","orcid":"0000-0001-7844-0856","position":4,"is_corresponding":false},{"id":1656537,"name":"Michael Grever","orcid":null,"position":5,"is_corresponding":false},{"id":767147,"name":"Adam S. Kittai","orcid":"0000-0002-4891-6144","position":6,"is_corresponding":false},{"id":278927,"name":"Kerry A. Rogers","orcid":"0000-0001-5748-7874","position":7,"is_corresponding":false},{"id":320324,"name":"Dan Jones","orcid":"0000-0002-4688-3780","position":8,"is_corresponding":false},{"id":249998,"name":"Weiqiang Zhao","orcid":"0000-0001-6560-2780","position":9,"is_corresponding":false},{"id":252809,"name":"Nyla A. Heerema","orcid":null,"position":10,"is_corresponding":false},{"id":278929,"name":"Lynne V. Abruzzo","orcid":"0000-0001-6113-7447","position":11,"is_corresponding":false},{"id":1638985,"name":"Jennifer Woyach","orcid":null,"position":12,"is_corresponding":false},{"id":1161336,"name":"Cecelia Miller","orcid":"0000-0001-6110-6069","position":13,"is_corresponding":false},{"id":457061,"name":"Matthew R. Avenarius","orcid":"0000-0001-9516-5163","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:p>\n                    Fluorescence in situ hybridization (FISH) to detect the recurrent cytogenetics abnormalities deletion 13q, trisomy 12, deletion 11q, and deletion 17p is important for prognostication in chronic lymphocytic leukemia (CLL). A subset of patients are negative for each of these abnormalities (normal 12/13/11/17 FISH), and outcomes are heterogenous within this group. To elucidate variables important for prognostication in this subgroup we conducted a retrospective analysis of 280 treatment‐naïve CLL patients with normal standard CLL FISH results. In a multivariable model, advanced Rai stage (\n                    <jats:italic>p</jats:italic>\n                     = 0.04, hazard ratio [HR] 1.24 (95% confidence interval [CI] 1.01–1.53)), unmutated immunoglobulin heavy chain gene (\n                    <jats:italic>IGHV</jats:italic>\n                    ) (\n                    <jats:italic>p</jats:italic>\n                     &lt; 0.0001, HR 5.59 (95% CI 3.63–8.62)) and\n                    <jats:italic>IGH</jats:italic>\n                    rearrangement by FISH (\n                    <jats:italic>p</jats:italic>\n                     = 0.02, HR 2.56 (95% CI 1.20–5.48)) were significantly associated with shorter time to first treatment. In a multivariable model for overall survival, increasing age at 5‐year increments (\n                    <jats:italic>p</jats:italic>\n                     &lt; 0.0001, HR 1.55 (95% CI 1.25–1.93)), unmutated\n                    <jats:italic>IGHV</jats:italic>\n                    (\n                    <jats:italic>p</jats:italic>\n                     = 0.01, HR 5.28 (95% CI 1.52–18.35)) and gain of\n                    <jats:italic>REL</jats:italic>\n                    (\n                    <jats:italic>p</jats:italic>\n                     = 0.01, HR 4.08 (5% CI 1.45–11.49)) were significantly associated with shorter survival. Our study identifies variables important for refining prognosis for CLL patients with normal standard CLL FISH results.\n                  </jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37010242","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":null,"license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3134","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":["Humans","Chromosome Aberrations","Prognosis","In Situ Hybridization, Fluorescence","Retrospective Studies","Child, Preschool","Leukemia, Lymphocytic, Chronic, B-Cell"],"keywords":["Fluorescence in situ hybridization","Chronic Lymphocytic Leukemia","Ighv"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T19:42:24.445703Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}